Topotarget and Spectrum Pharmaceuticals announce an amendment to the companies’ existing License Agreement. Pursuant to the amendment, Spectrum Pharmaceuticals will carry the responsibility for the commercial manufacture of belinostat for a 5-year period with the possibility of renewal.
Help employers find you! Check out all the jobs and post your resume.
